Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Forest Laboratories
NCT07478744 · Generalized Anxiety Disorder
NCT06804525 · Major Depressive Episode (MDE), Major Depressive Disorder (MDD), and more
NCT06942429 · Social Anxiety Disorder, Separation Anxiety Disorder, and more
NCT07429578 · Generalized Anxiety Disorder (GAD), Chronic Insomnia
NCT06661460 · ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Specific Phobia, and more
Forest Investigative Site 023
Birmingham, Alabama
Forest Investigative Site 013
Phoenix, Arizona
Forest Investigative Site 036
Beverly Hills, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions